SCHEDULE 13D/A: Silence Therapeutics Insider Richard Griffiths Boosts Stake with $1.6 Million ADS Purchases

Richard Ian Griffiths, a director and controlling shareholder of Silence Therapeutics Plc, has significantly increased his beneficial ownership in the company through recent open market purchases totaling $1.6 million.

Summary

• This document is Amendment No. 7 to the Schedule 13D filing for Silence Therapeutics Plc.
• Richard Ian Griffiths, a director and controlling shareholder, acquired an aggregate of 550,000 American Depositary Shares (ADSs) in open market transactions.
• These purchases occurred between April 1, 2025, and April 23, 2025, for a total price of approximately $1.6 million.
• The funds for these acquisitions were sourced from companies controlled by Mr. Griffiths or his personal funds.
• Following these transactions, Mr. Griffiths' aggregate beneficial ownership in Silence Therapeutics Plc stands at 30,933,897 ordinary shares, representing 21.8% of the company's outstanding shares.
• Ora Capital Limited, an entity controlled by Mr. Griffiths, beneficially owns 19,221,525 ordinary shares, which accounts for 13.6% of the class.
• The beneficial ownership percentages are calculated based on 141,664,074 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's Statement of Capital filed on December 11, 2024.
• Each ADS represents three ordinary shares of Silence Therapeutics Plc.

Sentiment

Score: 8

Explanation: The significant open market purchases by a director and controlling shareholder indicate strong insider confidence, which is generally viewed positively by the market.

Positives

• Significant insider buying by Richard Ian Griffiths, a director and controlling shareholder, signals strong confidence in Silence Therapeutics Plc's future prospects.
• Mr. Griffiths' acquisition of 550,000 ADSs for $1.6 million demonstrates a substantial personal investment in the company.
• The increase in Mr. Griffiths' beneficial ownership to 21.8% aligns his interests more closely with those of other shareholders.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Richard Ian Griffiths, a director and controlling shareholder, demonstrated confidence in the company through significant open market purchases of ADSs, funded by his personal and controlled company funds.

Industry Context

This filing is a disclosure of beneficial ownership changes by a significant insider and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The increased stake by a controlling shareholder may be perceived as a positive signal, potentially boosting investor confidence and aligning management interests with shareholder value.

Next Steps

• Richard Ian Griffiths will continue to file amendments to Schedule 13D if there are further material changes to his beneficial ownership in Silence Therapeutics Plc.

Key Dates

Recommendation

Keywords

Silence Therapeutics, Richard Ian Griffiths, Ora Capital Limited, Schedule 13D, beneficial ownership, ADSs, ordinary shares, insider buying, shareholding, investment